Targets › CGAS
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Apr 2029.
Nucleotidyltransferase that catalyzes the formation of cyclic GMP-AMP (2',3'-cGAMP) from ATP and GTP and plays a key role in innate immunity. Catalysis involves both the formation of a 2',5' phosphodiester linkage at the GpA step and the formation of a 3',5' phosphodiester linkage at the ApG step, producing c[G(2',5')pA(3',5')p]. Acts as a key DNA sensor: directly binds double-stranded DNA (dsDNA), inducing the…. (UniProt, Q8N884)
Open in Phaseline: the race on CGAS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chinese PLA General Hospital | Manganese Chloride cGAS-STING pathway activator | CGAS, STING1 | Phase 3 | Ovarian Cancer | Apr 2029 |
Ovarian Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.